What are the indications, dosages, and alternatives for Pregabalin (Lyrica)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pregabalin (Lyrica): Indications, Dosages, and Alternatives

Pregabalin is indicated for neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury-associated pain), adjunctive therapy for partial-onset seizures, and fibromyalgia, with dosing based on indication and renal function. 1, 2

Indications

FDA-Approved Indications:

  • Neuropathic Pain
    • Diabetic peripheral neuropathy
    • Postherpetic neuralgia
    • Neuropathic pain associated with spinal cord injury
  • Epilepsy: Adjunctive therapy for partial-onset seizures in patients 1 month of age and older
  • Fibromyalgia

Dosing Recommendations by Indication

1. Diabetic Peripheral Neuropathy

  • Starting dose: 50 mg three times daily (150 mg/day)
  • Target dose: 300 mg/day (maximum recommended)
  • Titration: May increase to 300 mg/day within 1 week based on efficacy and tolerability 2

2. Postherpetic Neuralgia

  • Starting dose: 75 mg twice daily or 50 mg three times daily (150 mg/day)
  • Target dose: 150-300 mg/day
  • Maximum dose: 600 mg/day
  • Titration: May increase to 300 mg/day within 1 week; doses above 300 mg/day should be reserved for patients with ongoing pain who tolerate 300 mg/day 2

3. Neuropathic Pain Associated with Spinal Cord Injury

  • Starting dose: 75 mg twice daily (150 mg/day)
  • Target dose: 300-600 mg/day
  • Titration: May increase to 300 mg/day within 1 week; may further increase to 600 mg/day after 2-3 weeks if needed 2

4. Adjunctive Therapy for Partial-Onset Seizures

  • Adults: Starting dose 150 mg/day, maximum 600 mg/day, divided into 2-3 doses
  • Pediatric patients ≥30 kg: 2.5 mg/kg/day initially, maximum 10 mg/kg/day (not exceeding 600 mg/day)
  • Pediatric patients <30 kg: 3.5 mg/kg/day initially, maximum 14 mg/kg/day 2

Dosing in Renal Impairment

Pregabalin requires dose adjustment in renal impairment as it is eliminated primarily by renal excretion 1, 2:

Creatinine Clearance (mL/min) Total Daily Dose Adjustment
≥60 No adjustment needed
30-59 150-300 mg/day
15-29 75-150 mg/day
<15 25-75 mg/day

For hemodialysis patients, administer a supplemental dose immediately following every 4-hour hemodialysis treatment 2.

Administration Guidelines

  • Pregabalin can be taken with or without food
  • Administer in 2-3 divided doses per day depending on indication
  • When discontinuing, taper gradually over at least 1 week to minimize withdrawal symptoms 2

Pharmacology and Pharmacokinetics

  • Mechanism of action: Binds to voltage-gated calcium channels at the α2-δ subunit, inhibiting neurotransmitter release 3
  • Absorption: Linear pharmacokinetics with ~90% bioavailability
  • Protein binding: Minimal
  • Metabolism: Not significantly metabolized
  • Elimination: Primarily renal excretion of unchanged drug (95%) 4
  • Half-life: Approximately 6 hours 4

Alternatives to Pregabalin

For Neuropathic Pain:

  1. First-line alternatives:

    • Gabapentin: 100-300 mg at bedtime initially, titrated to 900-3600 mg/day in divided doses 3, 1
    • Tricyclic antidepressants: Nortriptyline or desipramine 25 mg at bedtime initially, titrated to 150 mg/day 3, 1
    • SNRIs: Duloxetine (30 mg daily initially, target 60-120 mg daily) or venlafaxine (37.5 mg once or twice daily initially, target 75-225 mg daily) 3, 1
    • Topical lidocaine: 5% patch, up to 3 patches daily for 12-18 hours 3, 1
  2. Second-line alternatives:

    • Opioid analgesics: Reserved for refractory cases due to risk of addiction 1
    • Tramadol: 50 mg once or twice daily initially, titrated to 400 mg/day 3

Adverse Effects and Monitoring

  • Common adverse effects: Dizziness (27-46%), somnolence (15-25%), peripheral edema, weight gain 3, 1, 5
  • Monitoring:
    • Renal function (adjust dose accordingly)
    • Weight changes
    • Visual field changes (rare but reported) 6
    • Withdrawal symptoms if discontinued abruptly

Clinical Pearls and Pitfalls

  • Pregabalin may provide analgesia more quickly than gabapentin due to linear pharmacokinetics and more straightforward dosing 3
  • In the United States, pregabalin is a Schedule V controlled substance due to potential for abuse 3
  • For most neuropathic pain conditions, doses of 150 mg/day are generally ineffective; 300-600 mg/day are typically needed for efficacy 5
  • Only a minority of patients will have substantial benefit with pregabalin; NNTs for 50% pain relief range from 3.9 for postherpetic neuralgia to 11 for fibromyalgia 5
  • Avoid monotherapy fixation—many patients benefit from combination therapy with other agents 1
  • Pregabalin has not shown clear evidence of benefit in acute postoperative pain 5

References

Guideline

Neuropathic Pain Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pregabalin: a new agent for the treatment of neuropathic pain.

Drugs of today (Barcelona, Spain : 1998), 2005

Research

Pregabalin for acute and chronic pain in adults.

The Cochrane database of systematic reviews, 2009

Research

Pregabalin: new drug. Very similar to gabapentin.

Prescrire international, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.